e-learning
resources
Glasgow 2004
Sunday 05.09.2004
Therapy in asthma and COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Clinical features of steroid-resistant patients with severe steroid-dependent bronchial asthma
N. L. Shaporova, V. I. Trofimov, T. P. Ses, M. A. Petrova, O. A. Ivanova (St Petersburg, Russia)
Source:
Annual Congress 2004 - Therapy in asthma and COPD
Session:
Therapy in asthma and COPD
Session type:
Thematic Poster Session
Number:
890
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
N. L. Shaporova, V. I. Trofimov, T. P. Ses, M. A. Petrova, O. A. Ivanova (St Petersburg, Russia). Clinical features of steroid-resistant patients with severe steroid-dependent bronchial asthma. Eur Respir J 2004; 24: Suppl. 48, 890
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Related content which might interest you:
The immunological features of the severe steroid-resistant asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 479s
Year: 2003
The genetic markers of steroid-resistance in the patients with steroid-dependent bronchial asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 132s
Year: 2004
The glucocorticoid nuclear action peculiarities in the steroid-resistant patients with severe bronchial asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 32s
Year: 2003
Clinical response to mepolizumab in patients with severe eosinophilic asthma
Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma
Year: 2019
Use of budesonide suspension during the exacerbation of severe steroid-dependent bronchial asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 47s
Year: 2001
Clinical and histological impact of omalizumab in oral corticosteroid-dependent severe allergic asthma
Source: International Congress 2019 – Novel findings from asthma clinical trials
Year: 2019
Clinical profile of patients with adult-onset eosinophilic asthma
Source: ERJ Open Res 2016: 00100-2015
Year: 2016
Risk of bronchiectasis in bronchial asthma: steroid-dependent
versus
non-steroid-dependent asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 508s
Year: 2005
Characterisation of severe, steroid-dependent asthma patients who initiate biologics versus those who do not
Source: Virtual Congress 2021 – Severe asthma: evaluation using patient-reported outcome measures (PROMs) and biomarkers, comorbidities and treatments
Year: 2021
Mepolizumab efficacy in patients with severe eosinophilic asthma and bronchiectasis
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
The effectiveness of omalizumab in steroid-dependent asthma patients
Source: Annual Congress 2010 - Asthma: clinical aspects and treatment
Year: 2010
Heterogeneous response of airway eosinophilia to biologics in severe asthma patients
Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies
Year: 2021
Rapid Benralizumab effectiveness in patients with severe eosinophilic asthma and bronchiectasis
Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Year: 2020
Effects of omalizumab on markers of eosinophilic inflammation in patients with severe allergic asthma
Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD
Year: 2011
Experience with Mepolizumab in a cohort of patients with eosinophilic severe persistent asthma
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
Pathophysiology of non-eosinophilic severe asthma
Source: International Congress 2017 – Pathophysiology and emerging therapies for severe asthma
Year: 2017
Clinical features and their link with asthma exacerbations amongst aspirin-induced asthmatics
Source: Annual Congress 2010 - Asthma aspect of diagnosis and criteria for follow-up
Year: 2010
Impact of omalizumab in patients with severe asthma
Source: Annual Congress 2009 - Aspects of uncontrolled asthma
Year: 2009
Clinical features of metamizole intolerant patients with/without bronchial asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 422s
Year: 2002
Pathophysiology of severe non-allergic asthma
Source: International Congress 2019 – Pathophysiology and clinical insights into severe non-allergic asthma
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept